RecruitingPhase 4NCT07218341

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor

Eli Lilly and Company

Enrollment

150 participants

Start Date

Mar 9, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia Lymphoma, Small Lymphocytic

Summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria1

This is not applicable to this study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPirtobrutinib

Administered orally

DRUGIdelalisib

Administered orally

Locations(53)

Mitchell Cancer Institute

Mobile, Alabama, United States

Arizona Oncology Associates, P.C. - HOPE

Tucson, Arizona, United States

Cancer Specialists, LLC

Jacksonville, Florida, United States

Minnesota Oncology Hematology, P.A.

Coon Rapids, Minnesota, United States

Cayuga Cancer Center

Ithaca, New York, United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York, United States

Oncology Hematology Care Inc

Cincinnati, Ohio, United States

Texas Oncology - Paris

Fort Worth, Texas, United States

US Oncology - Texas Oncology

Kyle, Texas, United States

Liverpool Hospital

Liverpool, Australia

The Alfred Hospital

Melbourne, Australia

LKH - Universitätsklinikum der PMU Salzburg

Salzburg, Austria

AZ Delta

Roeselare, Belgium

Princess Margaret Cancer Centre - University Health Network

Toronto, Canada

Xuanwu Hospital Capital Medical University

Beijing, China

Hunan Cancer Hospital

Changsha, China

Sun Yat-sen University Cancer Center

Guangdong, China

Nanfang Hospital of Southern Medical University

Guangzhou, China

Gansu Provincial Cancer Hospital

Lanzhou, China

The First Affiliated Hospital of Nanchang University

Nanchang, China

Fudan University Shanghai Cancer Center

Shanghai, China

Taizhou Hospital of Zhejiang Province

Taizhou, China

Hematology Hospital of the Chinese Academy of Medical Sciences

Tianjin, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, China

Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, China

The Affiliated Hospital of Xuzhou Medical College

Xuzhou, China

Henan Cancer Hospital

Zhengzhou, China

University Hospital Center Zagreb

Zagreb, Croatia

Fakultni nemocnice Hradec Kralove

Hradec Králové, Czechia

Centre Henri Becquerel

Rouen, France

Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet

Budapest, Hungary

Debreceni Egyetem

Debrecen, Hungary

St. James's Hospital

Dublin, Ireland

Beaumont Hospital

Dublin, Ireland

Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo

Alessandria, Italy

Azienda Ospedaliera Universitaria Careggi

Florence, Italy

Presidio Ospedaliero Papardo

Messina, Italy

Fondazione IRCCS San Gerardo dei Tintori

Monza, Italy

Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia

Perugia, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

Tel Aviv Sourasky Medical Center

Tel Aviv, Italy

Azienda Ospedaliera S. Maria Di Terni

Terni, Italy

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma

Verona, Italy

Tokai University Hospital

Isehara, Japan

Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza

Brzozów, Poland

Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy

Bydgoszcz, Poland

Pratia Onkologia Katowice

Katowice, Poland

Instytut Hermatologii I Transfuzjologii

Warsaw, Poland

Hospital Universitario Marques De Valdecilla

Santander, Spain

Hospital Universitario Virgen Del Rocio

Seville, Spain

Castle Hill Hospital

Hull, United Kingdom

St James's University Hospital

Leeds, United Kingdom

GenesisCare

Newmarket, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07218341

Related Trials

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

NCT067929942 locations

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559196 locations

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872167 locations

Understanding Chronic Lymphocytic Leukemia

NCT040285311 location